15
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      A Subset of Protective γ 9δ 2 T Cells Is Activated by Novel Mycobacterial Glycolipid Components

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          γ 9δ 2 T cells provide a natural bridge between innate and adaptive immunity, rapidly and potently respond to pathogen infection in mucosal tissues, and are prominently induced by both tuberculosis (TB) infection and bacillus Calmette Guérin (BCG) vaccination. Mycobacterium-expanded γ 9δ 2 T cells represent only a subset of the phosphoantigen {isopentenyl pyrophosphate [IPP] and ( E)-4-hydroxy-3-methyl-but-2-enylpyrophosphate [HMBPP]}-responsive γ 9δ 2 T cells, expressing an oligoclonal set of T cell receptor (TCR) sequences which more efficiently recognize and inhibit intracellular Mycobacterium tuberculosis infection. Based on this premise, we have been searching for M. tuberculosis antigens specifically capable of inducing a unique subset of mycobacterium-protective γ 9δ 2 T cells. Our screening strategy includes the identification of M. tuberculosis fractions that expand γ 9δ 2 T cells with biological functions capable of inhibiting intracellular mycobacterial replication. Chemical treatments of M. tuberculosis whole-cell lysates (MtbWL) ruled out protein, nucleic acid, and nonpolar lipids as the M. tuberculosis antigens inducing protective γ 9δ 2 T cells. Mild acid hydrolysis, which transforms complex carbohydrate to monomeric residues, abrogated the specific activity of M. tuberculosis whole-cell lysates, suggesting that a polysaccharide was required for biological activity. Extraction of MtbWL with chloroform-methanol-water (10:10:3) resulted in a polar lipid fraction with highly enriched specific activity; this activity was further enriched by silica gel chromatography. A combination of mass spectrometry and nuclear magnetic resonance analysis of bioactive fractions indicated that 6- O-methylglucose-containing lipopolysaccharides (mGLP) are predominant components present in this active fraction. These results have important implications for the development of new immunotherapeutic approaches for prevention and treatment of TB.

          Related collections

          Most cited references61

          • Record: found
          • Abstract: found
          • Article: not found

          Targeting human {gamma}delta} T cells with zoledronate and interleukin-2 for immunotherapy of hormone-refractory prostate cancer.

          The increasing evidence that gammadelta T cells have potent antitumor activity suggests their value in immunotherapy, particularly in areas of unmet need such as metastatic carcinoma. To this end, we initiated a phase I clinical trial in metastatic hormone-refractory prostate cancer to examine the feasibility and consequences of using the gammadelta T-cell agonist zoledronate, either alone or in combination with low-dose interleukin 2 (IL-2), to activate peripheral blood gammadelta cells. Nine patients were enlisted to each arm. Neither treatment showed appreciable toxicity. Most patients were treated with zoledronate + IL-2, but conversely only two treated with zoledronate displayed a significant long-term shift of peripheral gammadelta cells toward an activated effector-memory-like state (T(EM)), producing IFN-gamma and perforin. These patients also maintained serum levels of tumor necrosis factor-related apoptosis inducing ligand (TRAIL), consistent with a parallel microarray analysis showing that TRAIL is produced by gammadelta cells activated via the T-cell receptor and IL-2. Moreover, the numbers of T(EM) gammadelta cells showed a statistically significant correlation with declining prostate-specific antigen levels and objective clinical outcomes that comprised three instances of partial remission and five of stable disease. By contrast, most patients treated only with zoledronate failed to sustain either gammadelta cell numbers or serum TRAIL, and showed progressive clinical deterioration. Thus, zoledronate + IL-2 represents a novel, safe, and feasible approach to induce immunologic and clinical responses in patients with metastatic carcinomas, potentially providing a substantially increased window for specific approaches to be administered. Moreover, gammadelta cell phenotypes and possibly serum TRAIL may constitute novel biomarkers of prognosis upon therapy with zoledronate + IL-2 in metastatic carcinoma.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Gammadelta T cells for immune therapy of patients with lymphoid malignancies.

            There is increasing evidence that gammadelta T cells have potent innate antitumor activity. We described previously that synthetic aminobisphosphonates are potent gammadelta T cell stimulatory compounds that induce cytokine secretion (ie, interferon gamma [IFN-gamma]) and cell-mediated cytotoxicity against lymphoma and myeloma cell lines in vitro. To evaluate the antitumor activity of gammadelta T cells in vivo, we initiated a pilot study of low-dose interleukin 2 (IL-2) in combination with pamidronate in 19 patients with relapsed/refractory low-grade non-Hodgkin lymphoma (NHL) or multiple myeloma (MM). The objectives of this trial were to determine toxicity, the most effective dose for in vivo activation/proliferation of gammadelta T cells, and antilymphoma efficacy of the combination of pamidronate and IL-2. The first 10 patients (cohort A) who entered the study received 90 mg pamidronate intravenously on day 1 followed by increasing dose levels of continuous 24-hour intravenous (IV) infusions of IL-2 (0.25 to 3 x 106 IU/m2) from day 3 to day 8. Even at the highest IL-2 dose level in vivo, gammadelta T-cell activation/proliferation and response to treatment were disappointing with only 1 patient achieving stable disease. Therefore, the next 9 patients were selected by positive in vitro proliferation of gammadelta T cells in response to pamidronate/IL-2 and received a modified treatment schedule (6-hour bolus IV IL-2 infusions from day 1-6). In this patient group (cohort B), significant in vivo activation/proliferation of gammadelta T cells was observed in 5 patients (55%), and objective responses (PR) were achieved in 3 patients (33%). Only patients with significant in vivo proliferation of gammadelta T cells responded to treatment, indicating that gammadelta T cells might contribute to this antilymphoma effect. Overall, administration of pamidronate and low-dose IL-2 was well tolerated. In conclusion, this clinical trial demonstrates, for the first time, that gammadelta T-cell-mediated immunotherapy is feasible and can induce objective tumor responses.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Stimulation of human gamma delta T cells by nonpeptidic mycobacterial ligands.

              Most human peripheral blood gamma delta T lymphocytes respond to hitherto unidentified mycobacterial antigens. Four ligands from Mycobacterium tuberculosis strain H37Rv that stimulated proliferation of a major human gamma delta T cell subset were isolated and partially characterized. One of these ligands, TUBag4, is a 5' triphosphorylated thymidine-containing compound, to which the three other stimulatory molecules are structurally related. These findings support the hypothesis that some gamma delta T cells recognize nonpeptidic ligands.
                Bookmark

                Author and article information

                Contributors
                Role: Editor
                Journal
                Infect Immun
                Infect. Immun
                iai
                iai
                IAI
                Infection and Immunity
                American Society for Microbiology (1752 N St., N.W., Washington, DC )
                0019-9567
                1098-5522
                13 June 2016
                19 August 2016
                September 2016
                19 August 2016
                : 84
                : 9
                : 2449-2462
                Affiliations
                [a ]Division of Infectious Diseases, Allergy & Immunology, Edward A. Doisy Research Center, Saint Louis University School of Medicine, St. Louis, Missouri, USA
                [b ]Department of Microbiology, Immunology, and Pathology, Colorado State University, Fort Collins, Colorado, USA
                [c ]Proteomics and Metabolomics Facility, Colorado State University, Fort Collins, Colorado, USA
                Weill Cornell Medical College
                Author notes
                Address correspondence to Karen M. Dobos, Karen.Dobos@ 123456colostate.edu , or Daniel F. Hoft, hoftdf@ 123456slu.edu .
                [*]

                Present address: Isaac G. Sakala, Vaxine Pty. Ltd., Flinders Medical Centre/Flinders University, SA, Australia; Charles T. Spencer, Department of Biological Sciences, The University of Texas at El Paso, El Paso, Texas, USA.

                M.X. and D.C.H. contributed equally to this article.

                Citation Xia M, Hesser DC, De P, Sakala IG, Spencer CT, Kirkwood JS, Abate G, Chatterjee D, Dobos KM, Hoft DF. 2016. A subset of protective γ 9δ 2 T cells is activated by novel mycobacterial glycolipid components. Infect Immun 84:2449–2462. doi: 10.1128/IAI.01322-15.

                Article
                01322-15
                10.1128/IAI.01322-15
                4995917
                27297390
                c257665e-0196-4476-98b4-a0df34c23764
                Copyright © 2016 Xia et al.

                This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International license.

                History
                : 21 October 2015
                : 23 November 2015
                : 7 June 2016
                Page count
                Figures: 7, Tables: 1, Equations: 0, References: 73, Pages: 14, Words: 11203
                Funding
                Funded by: HHS | National Institutes of Health (NIH) http://dx.doi.org/10.13039/100000002
                Award ID: R01 AI48391
                Award ID: 2R01AI048391-09
                Award Recipient : Daniel F. Hoft
                Funded by: Bill and Melinda Gates Foundation http://dx.doi.org/10.13039/100000865
                Award ID: OPP1118659
                Award Recipient : Daniel F. Hoft
                Categories
                Microbial Immunity and Vaccines

                Infectious disease & Microbiology
                Infectious disease & Microbiology

                Comments

                Comment on this article